Marvai LifeSciences Buys Assets, IP From Molecular Assemblies

Dow Jones

01/29

By Paul Ziobro

Marvai LifeSciences has acquired assets and intellectual property from Molecular Assemblies at undisclosed terms.

Marvai, a San Diego company, said Tuesday that the acquisition would expand the ability of it and TriLink BioTechnologies to enable customers to develop next-generation mRNA and Crispr nucleic-acid based therapies.

Marvai Chief Executive Trey Martin said that Molecular Assemblies is an original leader in enzymatic oligo synthesis, and its team has made significant advancement in designing and developing an enzymatic DNA synthesis platform with advantages over traditional chemical synthesis.

Write to Paul Ziobro at paul.ziobro@wsj.com

(END) Dow Jones Newswires

January 28, 2025 16:14 ET (21:14 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2507526268"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2507526268\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2507526268?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-29 05:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2507526268","market":"hk","top_or_hot":-1,"title":"Marvai LifeSciences Buys Assets, IP From Molecular Assemblies","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Paul Ziobro \n</p>\n<pre>\n \n</pre>\n<p>\n  Marvai LifeSciences has acquired assets and intellectual property from Molecular Assemblies at undisclosed terms. \n</p>\n<p>\n  Marvai, a San Diego company, said Tuesday that the acquisition would expand the ability of it and TriLink BioTechnologies to enable customers to develop next-generation mRNA and Crispr nucleic-acid based therapies. \n</p>\n<p>\n  Marvai Chief Executive Trey Martin said that Molecular Assemblies is an original leader in enzymatic oligo synthesis, and its team has made significant advancement in designing and developing an enzymatic DNA synthesis platform with advantages over traditional chemical synthesis. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 28, 2025 16:14 ET (21:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Marvai LifeSciences Buys Assets, IP From Molecular Assemblies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarvai LifeSciences Buys Assets, IP From Molecular Assemblies\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-01-29 05:14</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Paul Ziobro \n</p>\n<pre>\n \n</pre>\n<p>\n  Marvai LifeSciences has acquired assets and intellectual property from Molecular Assemblies at undisclosed terms. \n</p>\n<p>\n  Marvai, a San Diego company, said Tuesday that the acquisition would expand the ability of it and TriLink BioTechnologies to enable customers to develop next-generation mRNA and Crispr nucleic-acid based therapies. \n</p>\n<p>\n  Marvai Chief Executive Trey Martin said that Molecular Assemblies is an original leader in enzymatic oligo synthesis, and its team has made significant advancement in designing and developing an enzymatic DNA synthesis platform with advantages over traditional chemical synthesis. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 28, 2025 16:14 ET (21:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4136","symbol_name":"紙材料包裝","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2507526268","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507526268","pubTimestamp":1738098840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Marvai LifeSciences has acquired assets and intellectual property from Molecular Assemblies at undisclosed terms.Marvai, a San Diego company, said Tuesday that the acquisition would expand the ability of it and TriLink BioTechnologies to enable customers to develop next-generation mRNA and Crispr nucleic-acid based therapies.Marvai Chief Executive Trey Martin said that Molecular Assemblies is an original leader in enzymatic oligo synthesis, and its team has made significant advancement in designing and developing an enzymatic DNA synthesis platform with advantages over traditional chemical synthesis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4136":"纸材料包装","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","BK4121":"生命科学工具和服务","MRVI":"Maravai LifeSciences Holdings, Inc.","IP":"国际纸业"},"translate_title":"Marvai LifeSciences从Molecular Assemblies购买资产和知识产权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRVI":0.9,"IP":1},"content_text":"By Paul Ziobro \n\n\n \n\n\n  Marvai LifeSciences has acquired assets and intellectual property from Molecular Assemblies at undisclosed terms. \n\n\n  Marvai, a San Diego company, said Tuesday that the acquisition would expand the ability of it and TriLink BioTechnologies to enable customers to develop next-generation mRNA and Crispr nucleic-acid based therapies. \n\n\n  Marvai Chief Executive Trey Martin said that Molecular Assemblies is an original leader in enzymatic oligo synthesis, and its team has made significant advancement in designing and developing an enzymatic DNA synthesis platform with advantages over traditional chemical synthesis. \n\n\n \n\n\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 28, 2025 16:14 ET (21:14 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}